Switzerland market view

Switzerland biotech and pharma directory

Swiss biotech, pharma, CDMO, and diagnostics companies — 35+ hand-reviewed profiles. Basel is the historic center of European pharma (Roche, Novartis, Bachem, Lonza); Lausanne and Schlieren add therapeutic developers (Idorsia, Basilea, Noema, BioVersys); Zug is a meaningful operator hub. Highest regulatory tier in Europe.

Evidence

Visible records36

Verified records36

Cities covered17

Regulated sites19

Avg sources / record0.0

In-depth analysis

Read the related market brief

Deep-dive editorial map of this region’s operators, capabilities, partnerships, and regulatory landscape.

Swiss Biotech Landscape 2026Map of Basel, Lausanne, Lugano operators including Lonza, Basilea, Idorsia, Noema, BioVersys, Gain Therapeutics, Alentis.Swiss vs German Biotech Manufacturing 2026Side-by-side comparison of Swiss + German manufacturing capacity, GMP/FDA inspections, and CDMO partner selection.European Anti-Infectives & AMR 2026Swiss anti-infectives cluster (Basilea Cresemba/Zevtera, BioVersys alpibectir/BV100) plus the European AMR therapeutics + diagnostics layer.

Featured records

Start with the strongest profiles

These are the best-covered records in this region and the right place to start a serious review.

4bases SA 4D Lifetec AG AB2 Bio Ltd.ADC Therapeutics SA

Full list

Regional records

36 regional records currently match the active filter.

Manno (Ticino) genetic-diagnostics company producing CE-IVD marked NGS reagent kits, analysis software, and diagnostic protocols for clinical laboratories, hospitals, and healthcare providers.

Lead: Fabio GrandiChief Executive Officer
Scale: CE-IVD reagent kit manufacturing

Cham (Zug) diagnostics startup developing 4D Lifetest, an ultra-precise blood test for early cancer detection based on the 4D-Comet assay technology, with CE-IVD certified lung, breast, prostate, and colon applications.

Lead: Giancarlo RizzoliChief Executive Officer
Scale: Diagnostic platform commercialization

EPFL Innovation Park (Lausanne) Phase 3 clinical-stage autoinflammatory disease biotech developing Tadekinig alfa for IL-18 driven rare diseases, with a 650 million USD partnership with Nippon Shinyaku for US commercialization.

Lead: Djordje FilipovicChief Executive Officer
Scale: Phase 3 clinical biologics development

Epalinges-based NYSE-listed (ADCT) antibody-drug conjugate company, with FDA-approved Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma and a broader oncology ADC pipeline.

Lead: Ameet MallikChief Executive Officer
Scale: Commercial ADC oncology

Geneva cell and gene therapy biotech with miRNA-mediated gene silencing technology, developing off-the-shelf cellular immunotherapies led by miCAR7, an allogeneic anti-CD7 CAR-T product.

Lead: Marco AlessandriniChief Executive Officer
Scale: Preclinical cell-therapy development

Basel nanomechanical diagnostics company developing the ARTIDISNet platform for accelerated cancer diagnosis through atomic force microscopy, a spin-off from the University of Basel Biozentrum.

Lead: Marija PlodinecChief Executive Officer and Co-Founder
Scale: Diagnostic platform commercialization

Barbengo-Lugano privately held pharmaceutical CDMO with more than forty years of industry experience, specializing in high-potency active pharmaceutical ingredients, antibody-drug conjugates, and recombinant proteins for third-party pharma partners.

Lead: Emanuela MalacridaChief Executive Officer
Scale: Commercial pharmaceutical CDMO manufacturing

Basel shielded-cell therapy biotech developing paired cell-shielding and immunotherapy portfolios for hematologic disorders, with 46 million CHF Series A financing from Versant Ventures' Ridgeline Discovery Engine.

Lead: Thomas FuchsChief Executive Officer
Scale: Preclinical cell-therapy development

Allschwil (Basel area) ETH Zurich spin-off developing off-the-shelf soluble T-cell receptor (TCR) therapeutics for solid tumours, with 15.5 million CHF seed financing and BaseLaunch backing.

Lead: Lars NiebaChief Executive Officer
Scale: Preclinical TCR therapeutic development

Plan-les-Ouates (Geneva) in vitro respiratory model specialist supplying MucilAir and SmallAir 3D airway epithelial cultures to pharma, cosmetics, agrochemical, and regulatory-testing customers worldwide.

Lead: Samuel ConstantChief Executive Officer and Co-Founder
Scale: Commercial in vitro tissue manufacturing

Lugano- and Bethesda-based clinical-stage biotech developing allosteric small-molecule therapies for rare and neurodegenerative diseases, Nasdaq-listed under GANX.

Lead: Gene MackPresident and Chief Executive Officer
Scale: Clinical-stage small-molecule development

Bern-headquartered nanomedicine biotech with a liposomal drug-delivery platform (Talineuren, Talidox) and production processes developed at the Marly Innovation Center, running Swiss clinical trials in breast cancer and Parkinson's disease.

Lead: Peter HalbherrChairman and General Manager
Scale: Clinical-stage liposomal therapeutics

Schlieren ETH Zurich spin-off pioneering industrial-grade 3D cell-based assays and scaffold-free organ-on-a-chip technology for drug safety and efficacy testing, with subsidiaries in the US and Germany.

Lead: Jan LichtenbergChief Executive Officer and Co-Founder
Scale: Industrial tools and assay manufacturing

Geneva 94,000-square-foot integrated biologics CDMO combining Selexis cell line development and KBI mammalian contract manufacturing at a single site operating within JSR Life Sciences.

Lead: Ulrich ValleySenior Vice President, Operations and Site Head, Geneva
Scale: Integrated biologics CDMO manufacturing

Geneva (Plan-les-Ouates) bispecific antibody biotech operating the kappa-lambda-body platform for native-human-structure multi-specific antibodies targeting oncology and immunology.

Lead: Nicolas FischerChief Executive Officer
Scale: Bispecific antibody discovery and development

Schlieren antibody-discovery biotech built on the proprietary DROPZYLLA microfluidic single-cell platform, with a Phase II lead program (potravitug) for BK polyomavirus in kidney transplantation and a 2026 CSL collaboration worth up to 328 million USD.

Lead: Erik van den BergChief Executive Officer
Scale: Late-stage clinical antibody development

Basel synthetic biology and AI biotech targeting undruggable conditions through AI-designed microbes that produce therapeutic molecules, an ETH Zurich Department of Biosystems Science and Engineering spin-off.

Lead: Steven SchmittChief Executive Officer
Scale: Pre-seed research operations

Basel clinical-stage CNS biotech developing therapies for orphan neurological disorders driven by imbalanced neuronal networks, built on ex-Roche assets and backed by Sofinnova Partners with a 103 million EUR financing.

Lead: Ilise LombardoChief Executive Officer
Scale: Clinical-stage CNS therapeutics

EPFL spin-off developing the Gri3D microwell array technology for reproducible organoid generation, marketed to pharma, diagnostics, and translational research customers from the EPFL Innovation Park in Lausanne.

Lead: Sylke HoehnelChief Executive Officer and Co-Founder
Scale: Research-tools and diagnostic service delivery

Schlieren proteomics company providing discovery, translational, and clinical proteomics services and software from a strong Swiss life-science tools platform.

Lead: Oliver RinnerChief Executive Officer and Co-Founder
Scale: Global proteomics platform

Basel biopharmaceutical CDMO with Swiss GMP operations spanning cell-line development, process development, and biologics manufacturing.

Lead: Samanta CimitanChief Executive Officer
Scale: Commercial and development-stage biologics platform

Basel immunotherapy company engineering cytokine-based treatments for cancer and immune disorders from a Swiss biotech platform.

Lead: Dario NeriChief Executive Officer
Scale: Clinical-stage immunotherapy platform

Basel biotech company developing Claudin-1 targeted therapeutics across fibrosis and oncology from a clinical-stage Swiss platform.

Lead: Mark PruzanskiChief Executive Officer
Scale: Clinical-stage therapeutics platform

Swiss CDMO with major operations in Bubendorf, providing drug-substance development, drug-product services, and commercial manufacturing for small molecules and biologics.

Lead: Stephan FritschiChief Executive Officer
Scale: Commercial and development-stage CDMO platform

Market view

Switzerland is the directory’s premium trust benchmark.

This layer covers Swiss manufacturing, CDMO, therapeutics, diagnostics, and supply infrastructure that often serves as a European quality reference point.

Practical value

Use this page for premium-market comparison.

Swiss records are most useful when you want to compare a high-trust standalone market against Germany, Poland, or the Baltics.

Browse by

Cities, categories, and compliance

Jump into a specific city, category, or compliance-standard page for a more focused view.

Cities

Basel (12)Lausanne (3)Schlieren (3)

Compliance standards

GMP-documented in Switzerland (11)GLP-documented in Switzerland (4)ISO-13485-documented in Switzerland (4)FDA-Inspected-documented in Switzerland (1)

Frequently asked questions

Questions about switzerland biotech and pharma directory

How many biotech companies are in Switzerland?

The Memel Biotech directory lists 35+ verified Swiss biotech, pharma, CDMO, and manufacturing companies, with the strongest cluster in Basel.

Why is Basel important for biotech?

Basel is the historic center of European pharma, home to global headquarters (Roche, Novartis), precision manufacturing (Bachem, Lonza), and CDMO operators at the highest regulatory tier. The tri-border region with Germany and France makes it Europe's densest industrial biotech cluster.

What is Switzerland known for in biotech?

Switzerland sets Europe's highest regulatory bar. Strengths: large pharma majors, peptide and biologics CDMOs (Bachem, Lonza), premium MedTech (Sonova, Straumann), and well-capitalized therapeutic developers (Idorsia, Basilea, Noema, BioVersys).

What compliance standards do Swiss biotech companies hold?

Swiss companies in the directory commonly hold GMP, ISO 13485, and GLP certifications. Many manufacturing sites also carry FDA inspection — Swiss CDMOs are a default choice for drugs that must meet US regulatory requirements.

Can I compare two Swiss biotech companies side by side?

Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.

Next step

Compare Switzerland with Germany, Poland, and Lithuania.

Move into Germany for industrial depth, Poland for market scale, or Lithuania for Baltic comparison against a premium reference market.

Open Germany Open Poland Open Lithuania